Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Struggling to keep your mid-month budget on track? Learn practical steps to identify overspending, reallocate funds, and implement quick tweaks that stabilize your finances.
23,349 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
When a top executive sells shares after exercising options, markets take note. This deep dive breaks down Kalvista's ...
The shift in AI spending is reshaping winners and losers. This article explains why a power-semiconductor-focused com...
Two giants in chip-design software compete for your next tech stock buy. This guide breaks down Cadence Design System...
A smart AI investment can kickstart long-term growth. This guide uncovers the best artificial intelligence (ai) ETF f...
Investors are watching Criteo's early 2026 results to gauge the ad-tech pioneer's progress in privacy-friendly target...
A high-stakes exit valued at about $5.5 million and a difficult first quarter have investors re-evaluating risk in bi...
A fintech founder chose financial discipline over prestige, turning down an invitation from President Obama to focus ...
A widening trust gap is pushing American workers into siloed teams and news feeds. Executives are racing to rebuild d...
This guide breaks down ameresco (amrc) 2025 earnings, what drives results, and how investors can position themselves ...
Strategy Inc. raised hundreds of millions by selling new common stock to buy bitcoin, while Michael Saylor posted a r...
A high-profile insider move in KE Holdings has prompted questions about BEKE stock and China’s housing market. This a...